Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Polaryx Therapeutics, Inc. (NASDAQ:PLYX) have been given a consensus rating of “Moderate Buy” by the five analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $7.67.

A number of equities research analysts have recently commented on PLYX shares. Weiss Ratings reiterated a “sell (e)” rating on shares of Polaryx Therapeutics in a report on Monday, September 28th. HC Wainwright initiated coverage on shares of Polaryx Therapeutics in a report on Thursday, July 9th. They issued a “buy” rating and a $7.00 price objective for the company. Wall Street Zen raised Polaryx Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Raymond James Financial initiated coverage on Polaryx Therapeutics in a research note on Thursday, August 13th. They set a “strong-buy” rating and a $6.00 target price on the stock. Finally, Zacks Research upgraded Polaryx Therapeutics to a “hold” rating in a research note on Friday, July 10th.

Polaryx Therapeutics Stock Performance

NASDAQ PLYX opened at $1.82 on Tuesday. The stock has a market cap of $90.73 million and a P/E ratio of -22.75. Polaryx Therapeutics has a fifty-two week low of $1.75 and a fifty-two week high of $48.91. The stock has a 50 day simple moving average of $2.04 and a two-hundred day simple moving average of $3.18.

Polaryx Therapeutics (NASDAQ:PLYX) last posted its earnings results on Thursday, August 13th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.02. Sell-side analysts predict that Polaryx Therapeutics will post -0.22 earnings per share for the current year.

Polaryx Therapeutics Company Profile

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.